Drug discovery. In this review, the current status of cardiovascular regenerative trials using ES and iPS cells is briefly discussed.
Introduction
Cardiovascular diseases are the major causes of death in industrialized countries. Cardiovascular cells are, therefore, one of the most important targets in regenerative medicine. The regeneration of cardiomyocytes, which principally cannot proliferate and regenerate in the adult, is particularly expected to bring new hopes to cure cardiac diseases. Many cell types, such as endothelial progenitor cells from blood or bone marrow, cardiac progenitor cells from the heart, mesenchymal cells from bone marrow or other tissues, and ES and iPS cells, are currently being examined as cell sources for cardiovascular regenerative cell therapy [1] . Previously, the authors established a novel ES and iPS cell differentiation system, which can reproduce the early cardiovascular development processes in vitro [2, 3, 4] . Using and expanding this system as a tool for differentiation studies, cell transplantation and drug discovery, we are trying to explore novel cardiovascular regenerative strategies. indicator of the lateral plate mesoderm [7] . Flk1 is also the earliest functional differentiation marker for blood and ECs [8] . The Flk1 ligand, VEGF, is a key factor for EC differentiation. VEGF-A heterozygotes die early in gestation due to failure in vascular system formation, indicating that strict regulation of VEGF function is critical in normal vascular formation [9] . Recent reports for various molecular markers and functional molecules for arterial, venous, and Prox1-positive lymphatic ECs are induced [13] times [15] . PKA activation increased the total EC number that appeared from Flk1 + cells, but had no effect on arterial-venous specification. give rise to two cardiac progenitor populations that exist in so-called, primary heart field and secondary heart field [1, 17, 18] . Primary heart field is derived from the anterior splanchnic mesoderm and form cardiac crescent. Primary heart field is positive for Nkx2.5, Tbx5, and Hand1, and gives rise to mainly the left ventricle. Secondary heart field originates from the pharyngeal mesoderm and is situated medially to the primary heart field. Secondary heart field is positive for isl1, Tbx1, FGF8 and 10, and gives rise to mainly the right ventricle, outflow tract and inflow region. In addition to these two populations, proepicardial cells and neural crest cells also contribute to the heart structure [1] .
Differentiation of cardiovascular cells from ES and iPS cells
Cardiomyocytes are one of the first cell types induced from ES cells.
Appearance of self-beating cells in EBs was reported four years after the derivation of mouse ES cells [19] . The stepwise method showed that ES cadherin -(FCV) cells [3] . Flk1, Nkx2.5, and/or islet1 were reported to mark multipotent cardiac progenitor population [20] . Though these markers mainly represent lateral plate mesoderm, primary heart field, and secondary heart field, respectively, these marker expressions overlap each other [21] . For example, islet1 is also expressed in Flk1 + mesoderm, and Nkx2.5 is expressed in both heart fields. These progenitor populations should therefore be partially shown to efficiently generate cardiomyocytes after cell transplantation [21] .
Recently, importance of non-cardiomyocytes in cardiac regeneration is highlighted as a source of various humoral factors that help cardiac regeneration in a paracrine fashion [30] . Transplantation of cardiomyocyte/non-cardiomyocyte mixtures may be a good strategy for efficient regeneration. Novel transplantation technologies such as cardiosphere (cardiac cell aggregates) [31] and cardiac cell sheets using temperature-responsive culture surface [32] , would support mixture transplantation strategies.
Cardiovascular progenitors, which can efficiently give rise to cardiomyocytes as well as endothelial cells and mural cells, should be a good cell source for mixture strategies. In addition to such technical hurdles, elimination of undifferentiated ES/iPS cells to avoid teratoma formation is, by far the most critical issue for the safety of ES/iPS cell therapy. Recently, an iPS cell-specific feature in the teratoma-forming propensity was reported, where some iPS cell lines showed a "differentiation-resistant" phenotype [33] . In a particular iPS cell lines, which may be incompletely reprogrammed, undifferentiated cells persist even after induction of differentiation resulting in teratoma formation after transplantation. Establishment of standard for safe iPS cells would be critical to develop iPS cell therapy. dl-sotarol). When inhibitory effects of substances on HERG current were evaluated using human cardiomyocytes prepared from human ES/iPS cells in vitro, the in vitro results precisely reflected in vivo QT elongation [34] . Human cell models, thus, are potent tool for drug safety test which may drastically simplify and facilitate drug development.
2) Cardiac regenerative drugs
It would be ideal if cardiac regeneration could be achieved with drugs.
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Some trials to discover small molecules which promote cardiomyocyte differentiation are being performed using ES cell differentiation systems.
Cardiogenol, ascorbic acid, isoxazolyl-serines, sulfonyl hydrazones, and so on are reported to enhance cardiomyocyte differentiation from ES cells using EB methods [35] . Nevertheless, as these substances were added to EBs (or P19 carcinoma cell lines) from the initial step of differentiation, target cells or processes to which these substances act on are unclear. For example, cardiogenol and sulfonyl hydrazones should act on mesoderm induction stage.
Differentiation-stage specific screening and evaluation using stepwise differentiation methods would be more powerful and suitable to discover and will continue to bring various new hopes in cardiovascular regeneration.
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